The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.
Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD.
Clin Infect Dis. 2013 Oct;57(7):1038-47
10 November 2013, by Pr Pedro Cahn
After 1 154 803 person-years of follow-up of 207 539 HIV-1 infected individuals aged ≥ 14 years in COHERE, 12 135 AIDS-defining illnesses occurred at a CD4 count ≥ 200/mm3. Incidence of AIDS-defining illnesses was significantly higher for patients with a current CD4 count between 500 and 749/mm3 (adjusted incidence rate ratio of 1.20 ; 95% CI : 1.10 – 1.32) compared to those with a current CD4 count between 750 and 999/mm3, but incidence rate did not further decrease in those with a current CD4 count above 1000/mm3. Findings in patients with CD4 count between 500 and 749/mm3 were stronger for malignant AIDS-defining illnesses (adjusted incidence rate ratio, 1.52; 95% CI, 1.25–1.86) than for nonmalignant ones (adjusted incidence rate ratio, 1.12; 95% CI, 1.01–1.25), compared to those with CD4 of 750–999 cells/mm3. In patients with viral load below detectable levels, results were similar.
previous item
